OpenCharities

This text was generated using OCR and may contain errors. Check the original PDF to see the document submitted to the regulator.

2025-06-30-accounts

Report of the Trustees and

Financial Statement

for the Year Ended 30 June 2025 for

Commonwealth Pharmacists Association Registered Charity 1176132

1 July 2024 to 30 June 2025

Contents
Report of the Trustees
Independent Auditor’s Report
Statement of Financial Activities
Balance Sheet
Statement of Cash Flows
Notes to the Financial Statements
Detailed Statement of Financial Activities		 Page
3-38
39-41
42
43
44
45-57
58

2

Commonwealth Pharmacists Association Report of the Trustees For The Year Ended 30th June 2025

The trustees submit their report together with the financial statements of the charity for the year ended 30th June 2025.

Chair’s Foreword

What a pleasure to write another Chair’s Foreword for the Commonwealth Pharmacists Association Annual Report. I am delighted to report a further very successful year, led by our excellent Chief Executive Victoria Rutter. My thanks to all the staff and volunteers and trustees both here in the UK and especially working incountry for their contributions to the work of the CPA.

In the course of the year we said goodbye to trustees Zaheer Babar and Claire Thompson (to whom thanks and best wishes for the future). Former President Rao Vadlamudi stepped down after the Council elections. Rao has been a long-standing and faithful supporter of the Association, and has given excellent support to the CEO and to other trustees. In the course of the year we were joined by James Davies, Phyllis Ocran Mattila and Andrea Shirtcliffe. It was good to see the Council holding an election for the trustees to represent it.

This Report reveals a continuing excellent range of programmes, and a strong financial base. The CPA Academy increases in strength and visibility as the home for our continuing education and leadership training programmes. I am happy to acknowledge here the generous financial support we receive from our backers (all listed elsewhere in the Report), and the continuing support of the Commonwealth and the Royal Pharmaceutical Society in facilitating our work.

Looking beyond FY 2025-26 there are some clouds on the horizon. The significant reduction in the UK’s overseas aid budget, and consequent ending of funding from which we have previously benefited, means that we may in the short term have to operate in a more limited way, and in the longer term identify different strategies and sources of funding to continue and expand the important work we do. The Chief Executive and her team continue to work identifying and winning grants, and the trustees are supporting them in this effort.

Objectives and Activities

The CPA’s charitable objectives are:

3

Commonwealth Pharmacists Association Report of the Trustees For The Year Ended 30th June 2025

1. Summary of Main Activities

An accredited organisation of the Commonwealth, the CPA is a registered charity, leading and developing the pharmacy profession for the benefit of the people of the Commonwealth. The CPA works collaboratively across the Commonwealth to empower pharmacists to improve health and well-being of the communities they serve. The CPA has a growing collaboration plan with WHO and is in ‘official’ relations, ensuring the strategic alignment of the CPA’s work to delivering the Sustainable Development Goals (SDGs).

For the year ended 30th June 2025, CPA’s strategy has been delivered across three key areas of work:

  1. Workforce Capability Building: Expansion of CPD delivery through online learning modules, webinars, face to face workshops and specialist training; Preparation for the launch of the CPA Academy; Collaboration with FIP around workforce data collection for WHO.

  2. Health Systems Strengthening: Continuation of our two award winning flagship AMR programmes (CwPAMS and SPARC; launch of a second cohort of African Leadership Fellows in AMS, the establishment of the first joint UK - African cohort and a mentorship scheme; Transition of the Voluntary Information Sharing Database work into the Heads of Procurement Network.

  3. Advocacy, Campaigns and Events: Outputs from the 2024 Commonwealth Civil Society Forum (CCSPF) and inputs in to the 2025 CCSPF, Heads of Government Meeting in Samoa, Annual Health Ministers meeting; Campaigns around Commonwealth Pharmacists Day and World Antimicrobial Awareness Week; Multiple publications and presence at key events and conferences; Drafting of Pandemic Preparedness report for WHO.

The details of activities delivered in each of these areas are outlined in section 3. For additional information visit www.commonwealthpharmacy.org

2. Public Benefit

Upon appointment, all trustees are required to sign a Code of Conduct that outlines the commitment to CPA’s charitable objectives and working for the benefit of the public. Trustees are formally briefed on and sent the constitution and links to the Charities Commission Guide on the Responsibilities of Trustees on appointment and asked to familiarise themselves with these documents, as part of the trustee induction process.

As the charity has grown significantly over the last few years, trustee training has been introduced - this included further emphasis on all Charities Commission’s Guidance, including that relating to public benefit.

3. Contribution made by Volunteers

A volunteer governance/risk advisor continued to support the work of the charity.

Several volunteers also work for the CPA, including seven individuals who contributed their skills and expertise as an extension of our research and programmes teams.

4

Commonwealth Pharmacists Association Report of the Trustees For The Year Ended 30th June 2025

Major activities carried out in the reporting period - 1st July 2024 - 30th June 2025

1.Workforce Capability Building

1.1 PharmAid

Background and Aim

The primary aim of PharmAid is to provide essential medicines information resources to pharmacists and healthcare professionals throughout the Commonwealth. This initiative has been a cornerstone of the CPA's commitment to fostering professional development and knowledge-sharing among its members for nearly five decades.

Countries

Although this is an initiative for the whole Commonwealth, 10 countries have so far more actively engaged with PharmAid: Lesotho, Malawi, Nigeria, Papua New Guinea, Uganda, Rwanda, Sierra Leone, Sri Lanka, St Vincent and The Grenadines, and Tanzania.

Start and End date

Start Date: PharmAid launched in the 1970s End date: Ongoing

This is an update for the reporting period: 1 July 2024 to 30 June 2025.

Transition to Digital Access, including current and future partnerships

The CPA has worked with the Royal Pharmaceutical Society to secure access to paper copies of the British National Formulary since the 1970s. With the publishing landscape shifting from print to digital, CPA has been actively scoping options to ensure continued access to high-quality medicines information. This work includes exploring digital delivery models, partnerships, and sustainable approaches to ensure that healthcare professionals across the Commonwealth are not left behind in the transition.

1.2 Continuing Professional Development – Online CPD platform

Background

The Continuing Professional Development (CPD) platform continues to provide pharmacists with free, highquality training to advance their professional skills and improve patient outcomes. Developed in partnership with National Pharmacy Associations (NPAs), the platform delivers courses that align with global health priorities set by the Commonwealth and WHO. Where possible, accreditation is secured through NPAs, allowing pharmacists to use their learning towards national CPD requirements.

Aim

To strengthen the global pharmacy workforce by equipping pharmacists with knowledge and skills to address priority health challenges, thereby improving health systems and patient outcomes.

5

Commonwealth Pharmacists Association Report of the Trustees For The Year Ended 30th June 2025

New Guinea, Rwanda, Saint Lucia, Samoa, Sierra Leone, South Africa, Sri Lanka, Saint Vincent & The Grenadines, Tanzania, Uganda, Zambia, and Zimbabwe.

Start and end date

Start date: 1 February 2021. Launched in February 2021, the CPD platform delivers new modules, resources, and webinars on a quarterly basis, supported by both Novartis-funded and wider CPA-led initiatives End date: Ongoing

This is an update for the reporting period: 1 July 2024 to 30 June 2025.

New Courses

Webinars and Workshops

Engagement and Growth

Accreditation and Recognition

Outcomes and Impact

6

Commonwealth Pharmacists Association Report of the Trustees For The Year Ended 30th June 2025

1.3 Critical Care Course (with UCLH)

Background

Since 2022, the CPA has partnered with University College London Hospitals (UCLH) to widen access to the “Fundamentals of Critical Care” 12-month training programme for pharmacists in low- and middle-income countries (LMICs). The course combines structured teaching with practical application, enabling participants to put their learning directly into practice. By building critical care expertise, pharmacists are better equipped to support the management of seriously ill patients, improve therapeutic outcomes, and strengthen the resilience of healthcare systems. The initiative continues to bridge a major training gap in LMICs while promoting sustainable improvements in patient care.

Aims of the CPA/UCLH collaboration

Countries (2025 cohort)

This year, 40 pharmacists from 11 countries are participating in the course:

Country Number of Learners
Cameroon 3
Eswatini 1
Gambia,The 3
Ghana 1
Kenya 1
Malawi 3
Papua New Guinea 1
Sri Lanka 2
Tanzania 11
Uganda 8
Zambia 6
Grand Total 40

Start and end date

Start Date: 1 Jan 2022 (Course first launched in 2022) End Date: Ongoing

This is an update for the reporting period: 1 July 2024 to 30 June 2025.

7

Commonwealth Pharmacists Association Report of the Trustees For The Year Ended 30th June 2025

Programme Description

The “Fundamentals of Critical Care” course is a year-long, fully virtual programme designed for pharmacists already practising in, or newly entering, critical care settings. Delivered via Microsoft Teams, it offers a structured learning pathway across 12–14 intensive care topics, giving participants both foundational knowledge and practical insights to apply directly in their clinical work.

Course Structure

Expected Outcomes

1.4 Pharmacy Workforce Data

Background

The CPA continues to work collaboratively with the WHO National Health Workforce Accounts (NHWA) and the International Federation of Pharmacists (FIP) to collate pharmacy workforce data to enhance its utilisation. This data can then be used for effective pharmacy workforce planning, quality assurance (ensuring pharmacists are suitably qualified and maintaining professional standards), to identify gaps in pharmacy access, and to advocate for the importance of pharmacists in healthcare systems.

Aims

Countries

The project targets all Commonwealth member countries since data can be used for workforce planning; data collection is mostly active in CPA member organisations.

8

Commonwealth Pharmacists Association Report of the Trustees For The Year Ended 30th June 2025

Start and End date

Start date: 1 Jan 2021 (Scoping initiated in 2021. Survey developed during Q1 2024 and launched in April 2024. Data collection and analysis conducted during this reporting period.

End Date: Ongoing (Report to be completed in the next reporting period in September 2025)

This is an update for the reporting period: 1 July 2024 to 30 June 2025.

Key outcomes and impact

2. Health Systems Strengthening

2.1 CwPAMS - Commonwealth Partnerships for Antimicrobial Stewardship

Background

The Commonwealth Partnerships for Antimicrobial Stewardship (CwPAMS) programme aims to tackle antimicrobial resistance (AMR) by supporting low- and middle-income countries (LMICs) to generate, share and use data to improve antimicrobial use and clinical practice, and encourage further investment in AMR. The programme is managed by CPA in partnership with the Global HealthPartnerships (GHP, formerly THET) and is funded by the UK Department of Health and Social Care’s Fleming Fund.

Aim

CwPAMS aims to leverage the expertise, particularly in pharmacy, of UK health institutions, volunteers and technical experts to strengthen the capacity of the national health workforce and institutions in Commonwealth countries around the following focus areas:

Countries

Eight countries across the African continent: Ghana, Kenya, Malawi, Nigeria, Sierra Leone, Tanzania, Uganda, Zambia. In partnership with the United Kingdom.

Start and End date

Start date: 1 April 2023 (launch of CwPAMS 2)

End date: Ongoing (CwPAMS 2 to conclude in March 2026 with final evaluation subsequently conducted)

9

Commonwealth Pharmacists Association Report of the Trustees For The Year Ended 30th June 2025

Phase 2 of CwPAMS (CwPAMS 2.0) started in April 2023 and concluded in March 2025. A new extension phase, CwPAMS 2.5, commenced in April 2025 and will run for one year until 31 March 2026.

Key outcomes and impact

The outcomes and impact of this reporting period are being presented in two parts, covering the completion of CwPAMS 2.0 and commencement of CwPAMS 2.5.

Over the two years of implementing CwPAMS 2.0 (April 2023 - March 2025), the following achievements were observed by the end of the implementation period:

2.1.1 Completion of CwPAMS 2.0

Achievements in numbers by end of March 2025:

Achievements in Narrative (July 2024-March 2025)

Advancement of Antimicrobial Stewardship (AMS) Workforce and Technical Capacity:

Workforce Training: Data from initial scoping exercises was used to develop targeted resources and advocacy documents, specifically within the microbiology and Substandard & Falsified Medicines (SFMeds) workstreams. These were presented at global advocacy meetings like CHOGM.

Shared Learning: Multiple shared learning opportunities were created, including successful face-to-face hub and spoke strengthening meetings that facilitated peer-to-peer knowledge transfer between partner sites.

10

Commonwealth Pharmacists Association Report of the Trustees For The Year Ended 30th June 2025

Country led substandard and falsified medicines (SFMs) webinars: The In-country Consultants and their respective national authorities created awareness on SFMs. CwPAMS and other national teams participated actively, in each of the webinars across the 8 countries.

Extensive microbiology report produced: Using data collected iteratively through CwPAMS 2, the CPA microbiology team developed a comprehensive report outlining critical findings and actionable recommendations to bolster laboratory capacity, optimise diagnostics, and integrate microbiology data into clinical practice. The report was disseminated to key stakeholders including DHSC and Mott MacDonald.

Strengthened Governance, Leadership, and Country Ownership:

Launch of the Uganda AMR Parliamentary Forum: In November 2024, The Ugandan Speaker of Parliament launched the Uganda AMR Parliamentary Forum. This significant milestone was achieved through collaborative efforts between CwPAMS In-Country Coordinators (ICCs), Fleming Fund country grantees, and key partners. During the launch, Members of Parliament pledged their commitment to advocating for increased funding to combat AMR.

Integration into National Systems: Demonstrating sustainability, findings from the programme's data management workstream are now being used to inform national advocacy efforts during key stakeholder meetings, ensuring evidence-based policy discussions.

Strategic Engagement and Collaboration for Sustainability:

United Nations General Assembly High-Level Meeting (HLM) on AMR : The CPA and GHP developed and disseminated policy briefs outlining actionable recommendations for the HLM. These briefs were widely disseminated through our network and media channels to key national and international stakeholders. The significant impact of the CwPAMS programme was recognised at the HLM, with the Director of Pharmaceutical Services in Ghana specifically praising its contribution to enhancing antimicrobial stewardship within the country.

World AMR Awareness Week November 2024 : CwPAMS actively participated in WAAW activities across the 8 countries, as well as awareness creation on GHP and CPA social media platforms with over 15,000 engaged in our posts. In-country, CwPAMS provided support to various WAAW activities, including engagement with national stakeholders, producing a song to promote AMR awareness (HP in Kenya), participating in AMR awareness walks (Kenya), and liaising with ZNPHI on implementation of celebratory activities (Zambia).

Presenting at Conferences: The CPA actively showcased the impact of the CwPAMS programme through extensive conference engagement. A total of 20 abstracts were submitted, with 12 accepted to date, and 10 published in peer-reviewed journals or conference proceedings. In addition, the programme was represented through 20 poster presentations and 5 oral presentations at major international forums. These included events such as the International Congress on Infectious Diseases (ICID), the Ecumenical Pharmaceutical Network Forum and the annual conferences of the International Pharmaceutical Federation and the Royal Pharmaceutical Society. This high level of dissemination not only highlighted key project successes but also strengthened CPA’s visibility and partnerships across a diverse range of global stakeholders.

Publications: The CwPAMS 1 (including also phase 1.5) Impact Report was developed and published on 31 October 2024. A scoping review on the application of the hub and spoke model in AMS programmes was published in the Journal of Biomedical Sciences.

11

Commonwealth Pharmacists Association Report of the Trustees For The Year Ended 30th June 2025

CwPAMS 2.0 concluded with several valuable lessons learned and a suite of practical resources including data, which were directly transferred to inform and accelerate the start of the CwPAMS 2.5 phase.

Sharing & Learning Events and ALF-A Fellowship Graduation sessions were held in each of the 8 CwPAMS countries during February and March 2025. Each event attracted high level national stakeholders and partners and was an opportunity to celebrate the successes of CwPAMS HPs, showcase the achievements of the ALF-A Fellows, and reflect on future priorities within AMR and the national context.

2.1.2 Commencement of CwPAMS 2.5 (April 2025-June 2025)

Key CwPAMS 2.5 Achievements to Date: AMR Workforce and Technical Capacity Development:

Strengthening AMR Leadership:

Advancing Community Engagement:

12

Commonwealth Pharmacists Association Report of the Trustees For The Year Ended 30th June 2025

Enhancing Sustainability and Country Ownership:

Monitoring, Evaluation, Research and Learning:

2.2 Africa Leadership Fellowship for AMS (ALF-A)

Background

Based on the success of the UK's Chief Pharmaceutical Officers Global Health Fellows programme, a similar fellowship programme, the Africa Leadership Fellowship-AMS (ALF-A), has been developed for mid-career pharmacists in Africa who were part of health partnerships CwPAMS phase 2. Thirty pharmacists from across 8 African CwPAMS2 countries were selected following a very competitive selection process and started the fellowship in October 2023. Since many eligible pharmacists who applied for ALF-A could not be offered a fellowship place, CPA applied for further funding for another cohort. The second cohort of 15 pharmacists commenced in January 2024 for the year-long fellowship.

Aims

ALF-A aimed to:

Countries

Eight countries : Ghana, Kenya, Malawi, Nigeria, Tanzania, Uganda, United Kingdom, and Zambia.

Start and End date

Start date: October 2023

End date: Ongoing (final evaluation currently being conducted and anticipated to be concluded in Dec 2025)

This is an update for the reporting period: 1 July 2024 to 30 June 2025.

13

Commonwealth Pharmacists Association Report of the Trustees For The Year Ended 30th June 2025

Key outcomes and impact

Graduation and recognition: Of the 45 pharmacists enrolled, 43 successfully completed the fellowship and were awarded the Fellowship certificate.

Dissemination of learning: Graduation events were held integrated into CwPAMS 2.0 Learning and Sharing Events. Fellows presented their projects as poster displays, with a winning poster recognised in each country. Capacity building: Fellows implemented AMS projects within hospitals and community settings, contributing to local stewardship interventions and policy influence.

Leadership development: Through mentorship and training, fellows have taken on new leadership roles, becoming AMS champions within their institutions and at national level.

Monitoring, Evaluation and Communication of impact

2.3 UK-Africa Leadership Fellowship for AMS (UK-ALF-A)

Background

In 2024, CPA secured funding to deliver a combined UK-ALF-A Fellowship under the CwPAMS 2.5 extension, starting in April 2025. Forty Fellows, 20 UK-based and 20 from Ghana, Kenya, Malawi, Nigeria, Tanzania, Uganda, and Zambia, enrolled.

In parallel, 31 ALF-A alumni joined the CwPAMS Alumni Programme. Through the Alumni Mentoring Programme, they provide structured, peer-led support to new UK-ALF-A Fellows while strengthening their own leadership growth. Alumni also facilitate breakout sessions during online action learning, and selected 10 are serving as tutors, giving feedback on project plans and reports submitted by current Fellows.

This creates a sustained, intergenerational community of practice that strengthens antimicrobial stewardship leadership across the UK and Africa.

14

Commonwealth Pharmacists Association Report of the Trustees For The Year Ended 30th June 2025

Aims

UK-ALF-A aims to:

Countries

Nine countries: Ghana, Kenya, Malawi, Nigeria, Sierra Leone, Tanzania, Uganda, United Kingdom, and Zambia.

Start and End date

Start date: 1 April 2025 ( launch of fellowship)

End date: Ongoing (Fellowships will end in March 2026 with final evaluation to be subsequently conducted).

This is an update for the reporting period: 1 July 2024 to 30 June 2025.

Key outcomes and impact

2.4 CwPAMS Alumni Mentoring Programme

Background

The CwPAMS Alumni Mentoring Programme was established to sustain and amplify the impact of the CwPAMS initiative. Recognising the wealth of expertise built through successive phases of CwPAMS, the programme connects experienced alumni with new and emerging leaders in AMS. By fostering peer-to-peer learning, professional development, and leadership support, the mentoring programme strengthens a growing network of AMS champions across the Commonwealth, ensuring that the skills, knowledge, and innovations developed through CwPAMS continue to shape practice and policy long after formal project cycles end.

15

Commonwealth Pharmacists Association Report of the Trustees For The Year Ended 30th June 2025

Aims

The structured mentoring programme will:

Countries

Nine countries: Ghana, Kenya, Malawi, Nigeria, Sierra Leone, Tanzania, Uganda, United Kingdom and Zambia.

Start and End date

Start date: 1 May 2025 (launch of the mentorship scheme)

End date: Ongoing (mentoring of UK-ALF-A fellows will be completed in March 2026 but mentorship scheme will continue).

Key outcomes and impact

2.5 SPARC - Surveillance and Prescribing Support for Antimicrobial Stewardship Resource Capacity Building

Background

The Surveillance and Prescribing Support for Antimicrobial Stewardship Resource Capacity Building (SPARC) programme delivers innovative solutions to improve antimicrobial surveillance and prescribing in partner countries with a geographic focus in LMICs in Africa and Asia, to build workforce capability, capacity and resilience in health systems, in the drive for better global antimicrobial stewardship.

Aim

The SPARC programme has expanded from three workstreams to six:

16

Commonwealth Pharmacists Association Report of the Trustees For The Year Ended 30th June 2025

New workstreams

Countries

18 countries across two continents in Africa and Asia: Bangladesh, Eswatini, Ghana, Indonesia, Kenya, Malawi, Nepal, Nigeria, Pakistan, Papua New Guinea, Senegal, Sierra Leone, Sri Lanka, Tanzania, Timor Leste, Uganda, Zambia, Zimbabwe.

Start and End date

Start date: 1 Mar 2024 (launch on SPARC 2)

End date: Ongoing (SPARC 2 will close in March 2026 with final evaluation subsequently conducted)

SPARC phase 2 is currently underway and has been running since March 2024 set to conclude in March 2026 with final evaluation to be conducted after programme completion. Phase I was delivered from January 2022 to June 2023, with an interim extension between July 2023 to February 2024.

Key outcomes and impact

SPARC 2 Expansion

Strengthening AMS through Capacity Building - Data for action workshops delivered in 11 countries

17

Commonwealth Pharmacists Association Report of the Trustees For The Year Ended 30th June 2025

Digital Innovation: Malawi eMMS Pilot

Prescribing Companion App – Scaling Access and Impact

One Health initiatives and Multisectoral Engagement

18

Commonwealth Pharmacists Association Report of the Trustees For The Year Ended 30th June 2025

Conference Dissemination

The CPA continues to actively showcase the impact of the SPARC through conference engagement. A total of 3 abstracts were submitted, with 2 accepted to date and published in peer-reviewed journals or conference proceedings. In addition, the programme was represented through 4 poster presentations and 2 oral presentations at major international forums. These included events such as the East of England Global Health Conference, International Social Pharmacy Workshop and the annual conferences of the International Pharmaceutical Federation and the Royal Pharmaceutical Society. This high level of dissemination not only highlighted key project successes but also strengthened CPA’s visibility and partnerships across a diverse range of global stakeholders.

2.6 VIPSD - Commonwealth Voluntary Information and Price Sharing Database

Background

The Commonwealth Voluntary Information and Price Sharing Database (VIPSD) was established in response to the 2018 deliberations of the Commonwealth Health Ministers, who identified the need for a robust information-sharing mechanism among member states. The Commonwealth Secretariat spearheaded the development of VIPSD, an electronic database designed to promote equitable access to essential medicines and health commodities by providing critical procurement data. This initiative aims to support informed decision-making in the procurement of essential medicines. Despite being endorsed by Commonwealth Health Ministers in May 2021, the database's uptake and deployment have been limited.

Aim

In collaboration with the Commonwealth Secretariat, the CPA was commissioned to support a six-month project (June–November 2023) with the following objectives:

Countries

The project targeted up to 20 of the 56 Commonwealth member states, spanning five regions: the Eastern Caribbean, Southern African Development Community, Association of Southeast Asian Nations, Malta/Europe, and the Pacific.

Start and End date

Start date: 15 October 2021 (Launched of VIPSD) End date: Ongoing (paper to be published in July 2025)

19

Commonwealth Pharmacists Association Report of the Trustees For The Year Ended 30th June 2025

Key outcomes and impact

3. Advocacy, campaigns and events

3.1 Commonwealth Civil Society Policy Forum (CCSPF) 2024

Background

The CCSPF 2024 was convened by the Commonwealth Health Professions and Partners Alliance (CHPA) under the theme “Actionable Solutions to Building Resilience in Healthcare Systems within the Commonwealth, with an Emphasis on Small and Vulnerable States.” The forum fed recommendations into the 36th Commonwealth Health Ministers’ Meeting (36CHMM) which met in late May 2024 in Geneva alongside the 77th World Health Assembly. The resulting consensus paper from the forum was later prepared for peer review and published in May 2025.

Aims

Countries

All Commonwealth member countries.

Start and End Date

Start Date: 1 Jan 2024 (planning, followed by CCSPF, CHMM and CHOGM and associated outputs) End Date: 30 May 2025 (final paper published)

Key Outcomes and Impact

20

Commonwealth Pharmacists Association Report of the Trustees For The Year Ended 30th June 2025

3.2 UN High Level Meeting on AMR 2024

Background

The United Nations convened its second High-Level Meeting on Antimicrobial Resistance (AMR) in September 2024 in New York. The meeting brought together Heads of State, Ministers, civil society organisations, and technical agencies to take stock of progress since the 2016 political declaration and to galvanise global action to address AMR as a critical threat to health, food security, and sustainable development.

Aims

CPA’s engagement aimed to:

Countries

All Commonwealth member countries.

Start and End Date

Start Date: 1 June 2024 (preparatory advocacy and paper drafting) End Date: 30 September 2024 (meeting and dissemination)

Key Outcomes and Impact

CPA produced and disseminated two policy papers in advance of the meeting:

21

Commonwealth Pharmacists Association Report of the Trustees For The Year Ended 30th June 2025

Both papers were shared with Commonwealth delegations and UN agencies and fed into the wider CPA advocacy coordinated for the HLM. CPA’s contributions amplified the visibility of pharmacists as central to combating AMR, positioning pharmacy-led initiatives as scalable models for LMICs. Through its work with CHPA, CPA also helped ensure that references to health workforce strengthening, access to quality-assured antimicrobials, and stewardship were reflected in the HLM discussions and in draft commitments.

3.3 Commonwealth Heads of Government Meeting (CHOGM) 2024

Background

The 27th Commonwealth Heads of Government Meeting (CHOGM 2024) was hosted by Samoa in Apia (with retreat activities at Mulifanua). The summit took place in late October 2024, with leaders’ sessions held on 25– 26 October 2024 (ministerial meetings and fora preceded the summit). CHOGM 2024 brought together Heads of Government from the 56 Commonwealth member countries to agree shared priorities and communiqués on cross-cutting issues including climate, oceans, health and economic resilience.

Aims

Countries

All Commonwealth member countries.

Start and End Date

Start Date: 1 May 2024 (planning) End Date: 31 October 2024 (CHOGM held and output completed)

Key Outcomes and Impact

CPA produced and disseminated three policy papers in advance of the meeting:

A “Road to CHOGM24” narrative was published on CPA’s website documenting that many of the six recommendations from CCSPF 2024 were aligned with CHOGM documents/resolutions.

22

Commonwealth Pharmacists Association Report of the Trustees For The Year Ended 30th June 2025

CHOGM 2024 produced a number of high-level commitments and communiqués on climate resilience, oceans (the Apia Commonwealth Ocean Declaration), and sustainable development priorities which have relevance for health systems, particularly for small island and vulnerable states. These commitments provide leverage for downstream action on climate-health, health systems resilience and cross-sectoral partnership.

CPA’s “Road to CHOGM24” advocacy and CCSPF inputs helped ensure that health priorities - workforce resilience, climate-health action and equitable access to services - were visible in ministerial and Heads-level discussions, strengthening the case for health-sensitive implementation at national level.

3.4 Commonwealth Civil Society Policy Forum (CCSPF) 2025

Background

The CCSPF 2025 was convened by CHPA under the theme “Fit for our Commonwealth … toward a resilient and sufficient health and wellbeing workforce”. The online forum was held on 28 February 2025 building on prior CCSPF outputs. The three themes for the CCSPF 2025 Forum were:

Similarly to previous years, CPA was actively involved in the development and delivery of the CCSPF 2025.

Aims

Countries

All Commonwealth member countries.

Start and End Date

Start Date: 1 Jan 2025 (planning) End Date: 28 February 2025 (Forum held and report published)

23

Commonwealth Pharmacists Association Report of the Trustees For The Year Ended 30th June 2025

Key Outcomes & Impact

3.5 Commonwealth Health Ministers Meeting (CHMM) 2025

Background

The 37th Commonwealth Health Ministers Meeting (37CHMM) was held in Geneva, Switzerland, on 17 May 2025, on the margins of the World Health Assembly. The meeting brought together Commonwealth Health Ministers, senior officials and global health partners to consider civil society inputs (including CCSPF 2025) and to agree ministerial statements and ministerial priorities under the theme “Investing in Health: Sustainable Financing for an Equitable Commonwealth”.

Aims

Countries

All Commonwealth member countries.

Start and End Date

Start date: 1 Jan 2025 (planning)

End date: 17 May 2025. The CHMM meeting in Geneva was held immediately before the World Health Assembly (WHA) sessions that year.

Key Outcomes and Impact

24

Commonwealth Pharmacists Association Report of the Trustees For The Year Ended 30th June 2025

3.6 The role of Pharmacists in Pandemic Preparedness and Response

Background

In collaboration with the WHO, this project examines the critical role pharmacists play in pandemic preparedness and response. Drawing on evidence from the COVID-19 pandemic, the project aims to highlight the essential contributions of pharmacists in medicine access, vaccine delivery, supply chain management, public health education, countering misinformation, and supporting vulnerable communities, despite often being underrepresented in national emergency and health policy frameworks.

Aims

Countries

The project targets and has the potential to benefit all Commonwealth member countries since the outputs can be used for future planning; data collection is mostly active in CPA member organisations.

Start and End Date

Start Date: 1 Jan 2024

End Date: Ongoing (Final report to be completed in the next reporting period in October 2025). This is an update for the reporting period: 1 July 2024 to 30 June 2025.

Key Outcomes and Impact

3.7 World AMR Awareness Week 2024

Background

Every year as a condition of our agreement with the World Health Organisation, we participate in a range of global health campaigns to represent the voice of Commonwealth Pharmacy and advocate for shared health goals. Our flagship campaign from the range of WHO activities is World Antimicrobial Resistance Awareness Week, due to the volume of work CPA has done in this area over the last half decade.

Aims

25

Commonwealth Pharmacists Association Report of the Trustees For The Year Ended 30th June 2025

Countries

All Commonwealth member countries.

Start and End Date

Start date: 18 Nov 2024 End date: 24 Nov 2024

Key Outcomes and Impact

3.8 Commonwealth Pharmacists Day 2025

Background

Commonwealth Pharmacists Day is celebrated every year on June 16th as a triple celebration: to honour the convening of the first ever Commonwealth Pharmaceutical Conference in London in 1969 (which led to the formal institution of CPA on 1 January 1970 and is taken as our founding date), to remember our first President Albert Howells whose birthday happened to be on the same day, and to celebrate the pharmacy profession across the Commonwealth. The 2025 theme was chosen as a follow on from the theme of Commonwealth Day: “Six Continents. One Profession. Together, we thrive.”

Aims

Countries

All Commonwealth member countries.

Start and End Date

Start date: 1 May 2025 (planning) End date: 16 June 2025 (the day

Key Outcomes and Impact

26

Commonwealth Pharmacists Association Report of the Trustees For The Year Ended 30th June 2025

3.9 Communication highlights

Background

Throughout the year CPA undertakes a range of communication activities aimed at raising the organisation’s profile, celebrating the impact of its work and position itself as the authoritative voice of the pharmacy profession within the Commonwealth.

Aims

Countries

All Commonwealth member countries.

Start and End Date

Start date: 1 July 2024 End date: 31 June 2025

Key Outcomes and Impact

Future Activities

CPA is currently drafting a new Strategic Plan, creating a bold, pragmatic direction in response to a rapidly evolving global health and funding landscape. A key driver is the impending discontinuation of funding for CPA’s flagship antimicrobial resistance (AMR) programmes following the closure of the Fleming Fund in April 2026.

In terms of CPA’s ongoing programmes of work, future plans are outlined below.

4. Practice and Educational Resources

4.1 PharmAid

Next steps and Future Work

Survey work was initiated to understand member needs and preferred formats for accessing information. Further analysis and follow-up are required to finalise a model that balances accessibility, cost-effectiveness, and quality.

27

Commonwealth Pharmacists Association Report of the Trustees For The Year Ended 30th June 2025

4.2 Continuing Professional Development – Online CPD platform

Next steps and Future Work

Looking ahead, the CPA will deliver a strong pipeline of courses with the launch of Sickle Cell Disease (July 2025), Introduction to Quality Improvement (August 2025), Heart Failure (September 2025), Quality Improvement in Practice (October 2025), and the Cardiovascular Disease course (December 2025) supported by thematic webinars to strengthen clinical application and peer learning.

At the same time, the CPD platform is transforming into the CPA Academy in July 2025, with improved navigation, interactive discussion boards, and streamlined user access, creating a more dynamic and accurate learning environment. Alongside these upgrades, accreditation processes are advancing in Ghana, Tanzania, and Uganda to ensure local recognition of learning and support integration into national CPD systems. Together, these developments will establish the CPA Academy as a comprehensive hub for education, collaboration, and professional growth across the Commonwealth.

4.3 Critical Care Course (with UCLH)

Next steps and Future Work

We are currently seeking funding to expand access to a larger number of pharmacists in LMICs in the next cohort, commencing in April 2026.

4.4 Pharmacy Workforce Data

Next steps and Future Work

5. Health Systems Strengthening

5.1 CwPAMS - Commonwealth Partnerships for Antimicrobial Stewardship

Next steps and Future Work

Over the next year, CwPAMS 2.5 will focus on consolidating gains and embedding sustainable practices:

28

Commonwealth Pharmacists Association Report of the Trustees For The Year Ended 30th June 2025

5.2 Africa Leadership Fellowship for AMS (ALF-A)

Next Steps and Future Work

5.3 UK-Africa Leadership Fellowship for AMS (UK-ALF-A)

Next steps and Future Work

5.4 CwPAMS Alumni Mentoring Programme

Next steps and Future Work

5.5 SPARC - Surveillance and Prescribing Support for Antimicrobial Stewardship Resource Capacity Building

Next steps and Future Work

Given recent news about the close of the Fleming Fund, as we conclude SPARC 2 in March 2026, our focus is on sustaining impact and executing a responsible exit. This involves completing ongoing workstreams, embedding tools and processes within local systems, and supporting national partner institutions to sustain AMS gains beyond SPARC.

29

Commonwealth Pharmacists Association Report of the Trustees For The Year Ended 30th June 2025

5.6 VIPSD - Commonwealth Voluntary Information and Price Sharing Database Next steps and Future Work

30

Commonwealth Pharmacists Association Report of the Trustees For The Year Ended 30th June 2025

6. Advocacy, campaigns and other events

6.1 Commonwealth Civil Society Policy Forum (CCSPF) 2024

Next Steps and Future Work

6.2 UN High Level Meeting on AMR 2024

Next Steps and Future Work

6.3 Commonwealth Heads of Government Meeting (CHOGM) 2024

Next Steps and Future Work

6.4 Commonwealth Civil Society Policy Forum (CCSPF) 2025

Next Steps and Future Work

6.5 Commonwealth Health Ministers Meeting (CHMM) 2025

Next Steps and Future Work

31

Commonwealth Pharmacists Association Report of the Trustees For The Year Ended 30th June 2025

6.6 The role of Pharmacists in Pandemic Preparedness and Response

Next Steps and Future Work

6.7 World AMR Awareness Week 2024

Next Steps and Future Work

We plan to scale up our WAAW campaign in 2025 to take a bolder, more dynamic approach to the campaign, engaging more national stakeholders and international collaborators from within the Commonwealth family.

32

Commonwealth Pharmacists Association Report of the Trustees For The Year Ended 30th June 2025

Financial Review

1. Financial Review

The Charity has continued to grow after a stable income over the last two years preceded by a particularly rapid growth trajectory, reflected in total income for the year of £1.72m (2024: £1.19m).

The Charity’s core unrestricted fund stands at £243k (2024: £150k).

Designated funds are £43k (2024: £Nil) and restricted funds are £193k (2024: £167k) which reflect the unspent funds for project activity that extends over the next financial year.

The Charity begins the new financial year in a good financial position. The total funds carried forward are £479k (2024: £316k).

2. Reserves Policy

Reserves are held to help the charity operate efficiently. The unrestricted reserves are that part of the charity’s funds that are freely available to spend on the charity’s purposes. Whilst ensuring that the charity holds at least three months of unrestricted funds to cover running costs, the reserves policy also looks at building up reserves for unforeseen expenditure which will strengthen the resilience of the charity. Unforeseen expenditure can include a shortfall in income, temporary cash flow issues, uncontrolled costs, trustee liability, sudden closure. A decision to carry c. £100k in unrestricted reserves was deemed prudent and will be reviewed quarterly in light of a growing team of employed staff. This cost relates to three months of salaries and relevant redundancy costs.

3. Principal sources of funds:

33

Commonwealth Pharmacists Association Report of the Trustees For The Year Ended 30th June 2025

4. Principal Risks

The CPA has a strategic risk register in addition to those relating to individual projects. The risks to the charity have been categorised as operational, financial, regulatory, governance and external. The response and mitigations relating to these risks are detailed in the strategic risk register and are reviewed at least quarterly by the senior management team and more formally every quarter in liaison with the Board of Trustees. A further in-depth review of the risk register took place in May 2024, resulting in a much more comprehensive list of risks and a more standardised way of defining these.

Structure, Governance and Management

The charity is governed by the constitution accepted in December 2017 and adopted in July 2018 when the CPA officially began functioning as a Charitable Incorporated Organisation (CIO). This replaced the original constitution that related to the establishment of the unincorporated charity that was adopted in Dec 2015.

The charity is a CIO consisting of 31 (2024: 28) member organisations and over 8k (2024: 11k) individual members to date. Traditionally, the CPA has been an association of member organisations. Individual reach is expected to continue to grow in line with the relationships and collaborative working opportunities developed.

Trustees

In accordance with the constitution, there are:

The Trustees can fill any casual vacancy in their number and may co-opt nor more than three additional trustees, any person so appointed being entitled to hold office until the next AGM.

Any new trustees appointed are briefed by the board of Trustees of their legal obligation under charity and company law and the contents of the Memorandum and Articles of Association. They are given copies of the Memorandum and Articles of Association, recent Trustee meeting minutes and the latest financial information.

They are also directed towards the Charity Commission website, especially to booklets CC3 “The Essential Trustee” and CC3a, “Charity Trustee: what’s involved?”. Trustees are encouraged to attend appropriate training events which will help them know their responsibilities.

34

Commonwealth Pharmacists Association Report of the Trustees For The Year Ended 30th June 2025

Organisational Structure

The CPA is governed by the board of Trustees.

The Chief Executive Officer reports to the board of trustees and manages the day to day running of the organisation, working with the CPA team of staff, consultants, and volunteers.

The Trustees consider the Board of Trustees, the Chief Executive and the senior leadership team as comprising the key management personnel of the charity in charge of directing and controlling the charity and running and operating the charity on a day-to-day basis. All Trustees give their time freely and no trustee remuneration was paid in the year. Details of Trustee expenses and related party transactions are disclosed in notes 9 and 18 to the accounts.

Trustees are required to disclose all relevant interests and in accordance with the Trusts’ policy withdraw from decisions where a conflict of interest arises.

The pay of the Chief Executive and senior leadership team is reviewed annually and is normally increased in accordance with average earnings. The remuneration is reviewed to ensure that it is commensurate with similar roles.

The CPA’s council and regional assembly (previously referred to as ‘executive’) consist of representatives from the national pharmacy associations (NPAs) of the Commonwealth, from which the President and Vice president are elected. These bodies serve as an advisory board to the CPA, helping to set and deliver the strategy.

The CPA is in a unique position in terms of the organisation’s established and potential relationships, particularly in terms of:

Fundraising Standards Information

The charity does not raise funds from the general public and has had no complaints or concerns raised during the period in this respect.

35

Commonwealth Pharmacists Association Report of the Trustees

For The Year Ended 30th June 2025

Reference and Administration Details

Charity name: The Commonwealth Pharmacists Association

Charity Commission registered number: 1176132

Charity principal address: 66-68 East Smithfield, London, E1W 1AW

Trustees during the year were :

Tony Downes Chair Raymond Anderson Vice Chair Mary Anne Ciappara Immediate past president (Ex-officio) Biyi Oloko Treasurer

Claire Anderson Zaheer Babar Resigned 14th Aug 2024 Oksana Pyzik David Reissner Claire Thompson Resigned 19th Nov 2024 Rao Vadlamudi Ex-officio, Term ended 1st Oct 2025 Annagrace Malamsha President (Ex-officio) James Davies Andrea Shirtcliffe Phyllis Ocran Mattila

Appointed 1[st] Oct 2025 Appointed 4th Mar 2025 Appointed 4th Mar 2025 Appointed 4th Mar 2025

Other key personnel:

Victoria Rutter Chief Executive Officer Freya Liiv Finance & Business Manager Linda Tyler Finance & Administration Officer Beth Ward Strategic Lead: Workforce Capability Building Maxencia Nabiryo Head of Programmes Helena Rosado Monitoring, Evaluation and Research Lead Peter Gaffney Communications Manager

Independent Auditor:

Benjamin Hayes FCA Wenn Townsend

36

Commonwealth Pharmacists Association Report of the Trustees For The Year Ended 30th June 2025

Public Benefit

When planning the activities for the year, the trustees have complied with their duty in Section 4 of the Charities Act 2011 to have due regard to guidance published by the Charity Commission, including public benefit guidance.

The trustees have approved the report above and have authorised us to sign it on their behalf.

----- Start of picture text -----
_________
----- End of picture text -----

Tony Downes – Chair

----- Start of picture text -----
_________
----- End of picture text -----

Biyi Oloko – Treasurer

Date of approval: 13th January 2026

37

Commonwealth Pharmacists Association Report of the Trustees For The Year Ended 30th June 2025

Statement of Trustees responsibilities

The trustees are responsible for preparing the Trustees’ Annual Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

The law applicable to charities in England & Wales requires the trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charity and of the incoming resources and application of resources of the charity for that period.

In preparing these financial statements, the trustees are required to:

The trustees are responsible for keeping proper accounting records that disclose with reasonable accuracy at any time the financial position of the charity and enable them to ensure that the financial statements comply with the Charities Act 2011, the Charities (Accounts and Reports) Regulations 2008, and the provisions of the trust deed. They are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

38

Commonwealth Pharmacists Association Independent Auditor’s Report For The Year Ended 30th June 2025

Opinion

We have audited the financial statements of The Commonwealth Pharmacists Association (the ‘charity’) for the year ended 30[th] June 2025 which comprise the Statement of Financial Activities, the Balance Sheet, the Cash Flow statement and notes to the financial statements, including significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the auditor responsibilities for the audit of the financial statements section of our report. We are independent of the charity in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC’s Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the trustees’ use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the charity's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the trustees with respect to going concern are described in the relevant sections of this report.

Other information

The other information comprises the information included in the trustees' annual report, other than the financial statements and our auditor’s report thereon. The trustees are responsible for the other information. Our opinion on the financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in

39

Commonwealth Pharmacists Association Independent Auditor’s Report For The Year Ended 30th June 2025

the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

Matters on which we are required to report by exception

We have nothing to report in respect of the following matters in relation to which the Charities (Accounts and Reports) Regulations 2008 require us to report to you if, in our opinion:

Responsibilities of trustees

As explained more fully in the trustees’ responsibilities statement, the trustees are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the charity’s ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the charity or to cease operations, or have no realistic alternative but to do so.

Auditor responsibilities for the audit of the financial statements

We have been appointed as auditor under section 144 of the Charities Act 2011 and report in accordance with the Act and relevant regulations made or having effect thereunder.

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor’s report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below:

40

Commonwealth Pharmacists Association Independent Auditor’s Report For The Year Ended 30th June 2025

Because of the inherent limitations of an audit, there is a risk that we will not detect all irregularities, including those leading to a material misstatement in the financial statements or non-compliance with regulation. This risk increases the more that compliance with a law or regulation is removed from the events and transactions reflected in the financial statements, as we will be less likely to become aware of instances of noncompliance. The risk is also greater regarding irregularities occurring due to fraud rather than error, as fraud involves intentional concealment, forgery, collusion, omission or misrepresentation.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at: www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditor's report.

Use of our report

This report is made solely to the charity’s trustees, as a body, in accordance with Part 4 of the Charities (Accounts and Reports) Regulations 2008. Our audit work has been undertaken so that we might state to the charity’s trustees those matters we are required to state to them in an auditor’s report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charity and the charity’s trustees as a body, for our audit work, for this report, or for the opinions we have formed

Wenn Townsend Chartered Accountants, Statutory Auditor

Oxford

Date: 13th January 2026

Wenn Townsend is eligible to act as auditor in terms of section 1212 of the Companies Act 2006.

41

Commonwealth Pharmacists Association Statement of Financial Activities

For The Year Ended 30th June 2025

Note
Income from:
Donations and legacies
2
Charitable activities
Grants and contracts income
3
Individual subscriptions
Membership fees
Interest receivable
Total income
Expenditure on:
Charitable activities
4
Total expenditure
Net income/(expenditure)
Transfers between funds
16
Net movement in funds
Reconciliation of funds:
Total funds brought forward
Total funds carried forward		 Unrestricted
funds
£
10,520
214,000
4,879
20,504
239,383
7,921
257,824
216,311
216,311
41,513
94,995
136,508
149,817
286,325		 Restricted
funds
£
-
1,462,642
-
-
1,462,642
-
1,462,642
1,342,096
1,342,096
120,546
(94,995)
25,551
167,085
192,636		 2025
Total funds
£
10,520
1,676,642
4,879
20,504
1,702,025
7,921
1,720,466
1,558,407
1,558,407
162,059
-
162,059
316,902
478,961		 2024
Total funds
£
4,100
1,159,777
820
22,515
1,183,112
2,504
1,189,716
1,217,158
1,217,158
(27,442)
-
(27,442)
344,344
316,902

All income and expenditure have arisen from continuing activities

42

Commonwealth Pharmacists Association Balance Sheet

For The Year Ended 30th June 2025

Note
Fixed assets
Tangible assets
12
Current assets
Debtors
13
Cash at bank in hand
14
Creditors
Amounts falling due within one year
15
Net current assets
Total assets less current liabilities
Net assets
Funds
16
Unrestricted funds:
General funds
Designated funds
Restricted funds
Total funds		 2025
£
57
4,567
723,803
728,370
(249,466)
478,904
478,961
478,961
243,101
43,224
192,636
478,961		 2024
£
285
7,545
502,311
509,856
(193,239)
316,617
316,902
316,902
149,817
-
167,085
316,902

The financial statements were approved by The Board of Trustees on 13th January 2026 and were signed on its behalf by:

________ Tony Downes – Chair

________ Biyi Oloko – Treasurer

The notes on pages 45 to 57 form part of these financial statements.

43

Commonwealth Pharmacists Association

Statement of Cash Flows

For The Year Ended 30th June 2025

Reconciliation of net income to net cash flow from operating
activities:
Net income for the year
Depreciation
Interest receivable
Decrease in debtors
Increase in creditors
Cash generated from operations
Net cash from investing activities
Interest received
Net cash used in investing activities
Net increase in cash and cash equivalents
Cash and cash equivalents at the beginning of the year
Cash and cash equivalents at the end of the year		 2025
£
162,059
228
(7,921)
2,978
56,227
213,571
7,921
7,921
221,492
502,311
723,803		 2024
£
(27,442)
228
(2,504)
213,807
102,660
286,749
2,504
2,504
289,253
213,058
502,311

44

Commonwealth Pharmacists Association Notes to the Financial Statements For The Year Ended 30th June 2025

1. ACCOUNTING POLICIES

General information and basis of preparing the financial statements

The Commonwealth Pharmacists Association is a charitable incorporated organisation. The address of the registered office is given in the charity information on page 36 of these financial statements.

The financial statements of the charity, which is a public benefit entity under FRS 102, have been prepared in accordance with the Charities SORP (FRS 102) 'Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1st January 2019)', Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland and the Charities Act 2011. The financial statements have been prepared under the historical cost convention.

The financial statements are presented in sterling which is the functional currency of the charity and rounded to the nearest £1.

Going concern

There are no material uncertainties about the charity’s ability to continue so it is regarded as a going concern.

Income

All income is recognised in the Statement of Financial Activities once the charity has entitlement to the funds, it is probable that the income will be received, and the amount can be measured reliably.

Expenditure

Liabilities are recognised as expenditure as soon as there is a legal or constructive obligation committing the charity to that expenditure, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all cost related to the category. Where costs cannot be directly attributed to particular headings, they have been allocated to activities on a basis consistent with the use of resources.

Tangible fixed assets

Depreciation is provided at the following annual rates of write off each asset over its estimated useful life.

Office Equipment 25% straight line on cost

Fund’s structure

Funds held by the charity are either:

Unrestricted funds - these are funds which can be used in accordance with the Charity's objects at the trustees' discretion.

Designated funds – included within unrestricted funds, these are funds which can be used in accordance with the Charity’s objects at the trustees’ discretion and have been assigned for specific areas of activity.

45

Commonwealth Pharmacists Association Notes to the Financial Statements - continued For The Year Ended 30th June 2025

Restricted funds - these funds can only be used for restricted purposes within the objects of the Charity. Restrictions arise when specified by the donor or where funds are raised for restricted purposes.

Further explanations of the nature and purpose of each fund are included in the notes to the accounts.

Debtors and creditors receivable/payable within one year

Debtors and creditors with no stated interest rate and receivable or payable within one year are recorded at transaction price.

Employee benefits

When employees have rendered service to the charity, short-term employee benefits to which the employees are entitled are recognised at the undiscounted amount expected to be paid in exchange for that service.

The charity operates a defined contribution plan for the benefit of its employees. Contributions are expensed as they become payable.

46

Commonwealth Pharmacists Association

Notes to the Financial Statements - continued

For The Year Ended 30th June 2025

2. Donations and legacies

. Donations and legacies
Other donations
. Grants and contracts income
Unrestricted:
Novartis Pharma AG
Restricted:
Fleming (SPARC)
Fleming Fund (CwPAMS)
Fleming Fund (CwPAMS Alf-A 2)
Royal Pharmaceutical Society
Reckitt
Commonwealth Secretariat: Year of Youth Webinar
Gilead
. Charitable activities expenditure
Unrestricted
funds
£
Direct costs
53,800
Support costs (note 5)
162,511
216,311		 Restricted
funds
£
1,293,747
48,349		 2025
£
10,520
2025
£
214,000
865,955
549,868
-
25,000
6,819
-
15,000
1,676,642
2025
Total funds
£
1,347,547
210,860
1,558,407		 2024
£
4,100
2024
£
-
560,970
521,149
29,597
23,211
22,350
2,500
-
1,159,777
2024
Total funds
£
1,123,849
93,309
1,342,096 1,217,158

3. Grants and contracts income

4. Charitable activities expenditure

47

Commonwealth Pharmacists Association

For The Year Ended 30th June 2025

Notes to the Financial Statements - continued

5. Support costs

Staff costs
Travel and subsistence
Governance (note 6)
Information technology
Depreciation
Office costs
Bad debt
Other
Overhead contribution (note 7)
. Governance costs
Trustee expenses
Auditor remuneration
Other accountancy fees		 Unrestricted
funds
£
98,542
10,343
15,250
250
228
19,329
-
18,569
-
162,511		 Restricted
funds
£
44,334
3,904
-
-
-
111
-
-
-
48,349		 2025
Total funds
£
142,876
14,247
15,250
250
228
19,440
-
18,569
-
210,860
2025
£
5,726
7,620
1,904
15,250		 2024
Total funds
£
95,521
15,807
8,023
3,723
228
9,266
2,566
7,967
(49,792)
93,309
2024
£
470
7,000
553
8,023

6. Governance costs

7. Overhead contribution

In the prior year, overhead contributions included within grants and contracts receivable were accounted for by reallocating an amount from unrestricted support costs (as shown in note 5) to restricted direct costs. From the year ended 30th June 2025 onwards, these overhead contributions are instead accounted for as a transfer from restricted (or designated) funds to unrestricted (general) funds. The amount of overhead contributions recognised as transfers this year is £94,995. Total support costs would be £115,864 if these were accounted for in the same way as the prior year.

8. Net income for the year

Net income is stated after charging:

Net income is stated after charging:
2025 2024
£ £
Depreciation 228 228

48

Commonwealth Pharmacists Association Notes to the Financial Statements - continued For The Year Ended 30th June 2025

9. Trustees’ remuneration and benefits

There were no trustees' remuneration or other benefits for the year (2024: £Nil), except as outlined in Note 18.

One trustee (2024: no trustees) was reimbursed £84 (2024: £Nil) for travel expenses in the year. Additionally a total of £7,760 (2024: £470) was paid to third parties for trustees’ travel expenses.

The total amount of employee benefits received by key management personnel was £222,846 (2024: £254,815). The charity considers its key management personnel to comprise of the CEO, the Finance & Business Manager and the Strategic Lead: Workforce Capability Building.

10.Staff costs

Wages and salaries
Pension
Employer National Insurance contributions
Overtime		 2025
£
363,900
16,778
26,759
-
407,437		 2024
£
357,576
17,034
30,037
2,705
407,352

The average monthly number of employees during the year was as follows:

2025 2024
Staff 9 7

The number of employees who received total employee benefits (excluding employer pension costs) of more than £60,000 is as follows:

2025 2024
£60,001 - £70,000 2 1

The Charity has a pension scheme set up with NEST for the benefit of staff. New staff have the option of joining the NEST scheme or continuing to pay into their existing personal pensions.

The amount of pension contributions charged to the charity in the year was £16,778 (2024: £17,034). The amount of pension contributions outstanding at the end of the year was £3,258 (2024: £2,045).

49

Commonwealth Pharmacists Association Notes to the Financial Statements - continued For The Year Ended 30th June 2025

11.Comparative Statement of Financial Activities

Notes
Income from:
Donations
2
Charitable activities
Grant and contracts income
3
Individual subscriptions
Membership fees
Interest receivable
Total income
Expenditure on:
Charitable activities
4
Total expenditure
Net Income/(expenditure)
Transfers between funds
16
Net movement in funds
Reconciliation of funds:
Total funds brought forward
TOTAL FUNDS CARRIED FORWARD		 Unrestricted
funds
£
4,100
-
820
22,515
23,335
2,504
29,939
43,104
43,104
(13,165)
29,966
16,801
133,016
149,817		 Restricted
funds
£
-
1,159,777
-
-
1,159,777
-
1,159,777
1,174,054
1,174,054
(14,277)
(29,966)
(44,243)
211,328
167,085		 2024
Total funds
£
4,100
1,159,777
820
22,515
1,183,112
2,504
1,189,716
1,217,158
1,217,158
(27,442)
-
(27,442)
344,344
316,902

All income and expenditure have arisen from continuing activities

50

Commonwealth Pharmacists Association Notes to the Financial Statements - continued For The Year Ended 30th June 2025

12.Tangible fixed assets

12. Tangible fixed assets
Cost
At 1st July 2024
At 30th June 2025
Depreciation
At 1st July 2024
Charge for year
At 30th June 2025
Net book value
At 30th June 2025
At 30th June 2024
13. Debtors
Grant income
Subscriptions
Prepayments
Other debtors
14. Cash at bank in hand
Bank accounts		 2025
£
930
-
1,462
2,175
4,567
2025
£
723,803		 Office
Equipment
£
898
898
613
228
841
57
285
2024
£
5,830
250
930
535
7,545
2024
£
502,311

51

Commonwealth Pharmacists Association

Notes to the Financial Statements - continued

For The Year Ended 30th June 2025

15. Creditors: amounts falling due within one year

Trade creditors
Deferred income
Accruals
Pension contributions
HMRC creditor		 2025
£
102,805
124,500
12,615
3,258
6,288
249,466		 2024
£
46,183
121,275
14,258
2,045
9,478
193,239

Deferred income is made up of contracts for services relating to the 2025/26 financial year.

16. Movements in funds

Unrestricted funds
General fund
Designated funds
Novartis Pharma AG
Total unrestricted funds
Restricted funds
Fleming Fund (SPARC)
Fleming Fund (CwPAMS)
Fleming Fund (CwPAMS Alf-A)
Commonwealth Secretariat
Royal Pharmaceutical Society
Reckitt
Gilead
Total restricted funds
Total funds		 At 1 July
2024
£
149,817
-
149,817
107,956
18,073
25,611
2,192
-
13,253
-
167,085
316,902		 Incoming
resources
£
257,824
-
257,824
865,955
549,868
-
-
25,000
6,819
15,000
1,462,642
1,720,466		 Outgoing
resources
£
(72,529)
(143,782)
(216,311)
(747,024)
(539,340)
-
(2,192)
(25,000)
(13,540)
(15,000)
(1,342,096)
(1,558,407)		 Transfers
(92,011)
187,006
94,995
(59,538)
(9,846)
(25,611)
-
-
-
-
(94,995)
-		 At 30
June 2025
£
243,101
43,224
286,325
167,349
18,755
-
-
-
6,532
-
192,636
478,961

52

Commonwealth Pharmacists Association Notes to the Financial Statements - continued For The Year Ended 30th June 2025

Designated funds:

Focus Area 1 will be training delivered covering; Sickle Cell Disease, Malaria, Cardio Vascular Disease, Ophthalmology, Substandard and Falsified Medicines, and Leprosy.

Focus Area 2 will be the Pharmacists Leadership Programme.

The Novartis funds have been treated as designated as there is a detailed plan of activities.

Restricted funds:

S urveillance and P rescribing support for A ntimicrobial Stewardship R esource C apacity Building. Managed by Mott Macdonald.

SPARC commenced in October 21 originally for 9 months. After 2 extensions it finally closed on 30[th] June 2023. The CPA was invited to apply for a second round of funding. This application was successful giving funding for an extension which ran to February 2024.

Following this we have been awarded further funding to develop and grow the SPARC project in the existing and additional territories until March 2026.

- Fleming Fund (CwPAMS)

CwPAMS is a health partnership scheme funded by the UK Government Department of Health and Social Care’s Fleming Fund. Managed by GHP, previously THET. The CwPAMS networking platform was developed by BSAC for use by partners in the CwPAMS programme in partnership with the Commonwealth Pharmacists’ Association (CPA). The forum will allow the sharing of skills and knowledge between multidisciplinary NHS teams, including or led by pharmacists with hospitals in Ghana, Tanzania, Uganda and Zambia, and expand capacity for antimicrobial stewardship. This initial programme ran until June 2022. The small amount of underspend was carried over to CwPAMS 2.0. No underspend was carried forward to CwPAMS 2.5.

The programme commenced in July 2022 as a continuation of CwPAMS 1.5 and ran to June 2024. A restricted fund with a very detailed and strictly controlled budget in collaboration with THET. The figures introduced into the budget are lifted directly from the formal agreement. This was extended to CwPAMS 2, where we were able to continue our work and legacy. We are currently working towards the end of the final phase, CwPAMS 2.5 which will run until March 2026. Funds are received partly in advance and partly in arrears.

- Fleming Fund (CwPAMS Alf-A)

The African Leadership Fellowship-AMS, developed for mid-career pharmacists in Africa who are part of a CwPAMS 2 partnership. This work has continued, but is now included in the CwPAMS fund.

- Commonwealth Secretariat / VIPSD The Commonwealth Voluntary Information and Price

Sharing Database

Objectives:

53

Commonwealth Pharmacists Association Notes to the Financial Statements - continued For The Year Ended 30th June 2025

Grant of £24K received in advance from the Commonwealth Secretariat. The programme ran for 6 months from September to Feb 2024. The final academic journal was published in December 2024.

- RPS

An annual grant from the Royal Pharmaceutical Society of £25K to cover core salaries for the calendar year not covered by programmes.

- Reckitt

To run an educational programme, including but not limited to a train the trainer workshop covering Clinical Consultation Skills and expanding pharmacists scope of practice.

- Gilead

Gilead Sciences Inc. approved our request for funding to support a CPA run webinar for World AIDS Day: The Role of Pharmacists in Advancing HIV Care.

Transfers:

54

Commonwealth Pharmacists Association Notes to the Financial Statements - continued For The Year Ended 30th June 2025

Movement in funds - continued

2024

Unrestricted funds
General fund
Designated funds
Novartis Pharma AG
Total unrestricted funds
Restricted funds
Fleming Fund (SPARC)
Fleming Fund (SPARC Extension)
Fleming Fund (CwPAMS)
Fleming Fund (CwPAMS Alf-A 2)
Pfizer
Commonwealth Secretariat
Royal Pharmaceutical Society
Menarini AMS CPD
Reckitt
Total restricted funds		 At 1 July
2023
£
107,689
25,327
133,016
-
-
43,741
-
116,246
23,600
25,000
2,741
-
211,328
344,344		 Incoming
resources
£
29,939
-
29,939
217,468
343,502
521,149
29,597
-
2,500
23,211
-
22,350
1,159,777
1,189,716		 Outgoing
resources
£
(17,777)
(25,327)
(43,104)
(109,512)
(343,502)
(546,817)
(3,986)
(86,280)
(23,908)
(48,211)
(2,741)
(9,097)
(1,174,054)
(1,217,158)		 Transfers
29,966
-
29,966
-
-
-
-
(29,966)
-
-
-
-
(29,966)
-		 At 30
June 2024
£
149,817
-
149,817
107,956
-
18,073
25,611
-
2,192
-
-
13,253
167,085
316,902

Restricted funds:

- Pfizer - Medical Education Grant Initiative

To increase the number of Pharmacists in low/middle income countries (LMICs) accessing and completing locally relevant Continuing Professional Development (CPD) courses via an online CPD platform. The target population includes Latin America, Africa, the Middle East, Southeast Asia and beyond.

The core purpose of the CPD platform is to support in upskilling the pharmacy workforce, building capacity in health systems and ultimately improving patient care and safety. The objectives are:

55

Commonwealth Pharmacists Association Notes to the Financial Statements - continued For The Year Ended 30th June 2025

The total grant of £125,000 had been received and partially spent up to June 2023. The remaining funds of £116K have been fully spent in the current year.

- Menarini

The project aims to update the AMR/AMS CPD programme courses to align with international standards and incorporate behavioural change outcomes that can be assessed. In addition, other resources will be accessible to learners through the platform, transforming it into a world-class resource hub for AMR/AMS training.

Objectives:

Transfers:

17. Analysis of net assets between funds

2025
Tangible fixed assets
Cash at bank and in hand
Other net current liabilities		 General
fund
£
57
271,439
(28,395)
243,101		 Designated
funds
£
-
163,553
(120,329)
43,224		 Restricted
funds
£
-
288,811
(96,175)
192,636		 Total
funds
£
57
723,803
(244,899)
478,961

56

Commonwealth Pharmacists Association

Notes to the Financial Statements - continued For The Year Ended 30th June 2025

Analysis of net assets between funds – continued 2024

Tangible fixed assets
Cash at bank and in hand
Other net current liabilities		 General
fund
£
285
176,653
(27,121)
149,817		 Designated
funds
£
-
107,000
(107,000)
-		 Restricted
funds
£
-
218,658
(51,573)
167,085		 Total
fund
£
285
502,311
(185,694)
316,902

18. Related party disclosures

Donations from Trustees totalled £6,690 (2024: £3,930).

An amount of £2,000 was paid to one trustee during the year, but for work performed and completed prior to their appointment as a trustee. An amount of £26 was also paid to another trustee for services provided during the year.

In both cases, the provision of services was at or below a market rate basis, and no amounts were outstanding at the year end date.

57

Commonwealth Pharmacists Association

Notes to the Financial Statements - continued

For The Year Ended 30th June 2025

Detailed Statement of Financial Activities
Income from:
Donations and legacies
Charitable activities
Grants and contracts income
Membership fees
Individual subscriptions
Interest receivable
Total income
EXPENDITURE
Charitable Activities:
Direct costs and contractors’ fees
Gross salaries, NI and pension
Technical support
Accountancy and payroll
Insurance
Consultancy fees
Telephone, stationery, office supplies
Travel and subsistence
Subscriptions
Bank charges and exchange differences
Software
Staff welfare and training
Recruitment
Depreciation of IT equipment
Bad debt
Total expenditure
Net income/(expenditure)		 Unrestricted
funds
£
10,520
214,000
4,879
20,504
239,383
7,921
257,824
53,800
97,662
250
9,524
3,180
14,674
2,848
16,069
14,662
715
1,819
880
-
228
-
216,311
41,513		 Restricted
funds
£
-
1,462,642
-
-
1,462,642
-
1,462,642
1,293,747
44,334
-
-
-
-
111
3,904
-
-
-
-
-
-
-
1,342,096
120,546		 2025
Total funds
£
10,520
1,676,642
4,879
20,504
1,702,025
7,921
1,720,466
1,347,547
141,996
250
9,524
3,180
14,674
2,959
19,973
14,662
715
1,819
880
-
228
-
1,558,407
162,059		 2024
Total funds
£
4,100
1,159,777
22,515
820
1,183,112
2,504
1,189,716
1,074,057
89,785
3,723
7,553
4,927
1,565
3,105
16,277
3,026
1,475
3,135
3,912
1,824
228
2,566
1,217,158
(27,442)

This page does not form part of the statutory financial statements

58